Novo Plans Phase III Program To Pick Up Obesity Claim For Victoza
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novo Nordisk is moving ahead with plans to develop Victoza (liraglutide) for obesity now that U.S. regulators are comfortable with the GLP-1's risk/benefit profile